Syncona’s clinical portfolio comprises companies with the potential to treat patients across a range of conditions including: non-small cell lung cancer, melanoma, adrenomyeloneuropathy, Gaucher disease and liver transplantation using a variety of modalities, including cell therapy, gene therapy and biologics.
Unless stated all financials at 30 June 2023
Value of clinical portfolio
Number of clinical trials
Portfolio company Board seats